
Opinion|Videos|July 18, 2024
Patient Communication and Utilization of JAK Inhibitors in Atopic Dermatitis
Author(s)Ruth Ann Vleugels, MD, MPH, MBA
An expert in the treatment of atopic dermatitis shares her perspectives on patient communication and treatment optimization practices.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How do you educate and counsel patients who want to consider or are currently using a JAK inhibitor?
- How do you discuss treatment targets and manage patient expectations?
- What suggestions do you have for patients and healthcare professionals to optimize treatment of AD with JAK inhibitors?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
How Upadacitinib Could Expand Options for Severe Alopecia Areata, With Natasha Mesinkovska, MD, PhD
2
What Upadacitinib Could Mean for Younger Patients With Severe Alopecia Areata
3
FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis
4
Diabetes Dialogue: The International Diabetes Federation and Care Access in India, With Amit Gupta, MBBS, DNB
5



























































